mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels)

Riveiro-Barciela, Mar; Roade, Luisa; Martínez-Camprecios, Joan; Vidal-González, Judit; Rodríguez-Diez, Basilio; Perelló, Manel; Ortí, Guillermo; Robles-Alonso, Virginia; Berastegui, Cristina; Navarro, Jordi.
Gastroenterol. hepatol. (Ed. impr.) ; 46(10): 764-773, dic. 2023. tab
Artículo en Inglés | IBECS (España) | ID: ibc-228224

Documentos relacionados

  1. mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels).
  2. Absence of Persistent Hepatitis E Virus Infection in Antibody-Deficient Patients Is Associated With Transfer of Antigen-Neutralizing Antibodies From Immunoglobulin Products.
  3. Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients.
  4. Hepatitis E, what's the real issue?
  5. Epidemiology and treatment of hepatitis E in the liver transplantation setting: A literature review.
  6. Prevalence of active hepatitis E virus infection and efficacy of ribavirin treatment in renal allograft recipients.
  7. Seroprevalence of hepatitis E virus after pediatric liver transplantation.
  8. Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis.
  9. Hepatitis E virus infection.
  10. Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide: A case report with emphasis on geoepidemiology.